CMS announces reduced prices for 15 key Medicare Part D drugs starting in 2027, following the Inflation Reduction Act negotiations, targeting major cost savings in Medicare spending.

Comprehensive update on U.S. health insurance market dynamics including ACA subsidy uncertainty, Medicare specialty payment reforms, SNAP funding challenges, healthcare industry consolidations, pharmaceutical litigation, and emerging clinical innovations affecting insurance professionals.

Stay informed on the latest Q3 2025 developments in the Inflation Reduction Act's impact on pharmaceutical supply chains, Medicare negotiation programs, and drug pricing reforms with the Mintz IRA Update.

Pharmaceutical import tariffs are driving up health insurance premiums in the ACA small group market, as insurers anticipate higher drug costs and incorporate these risks into rate filings. This impacts employer health benefits and premium affordability.

Pharmaceutical companies are adopting direct-to-consumer drug sales, bypassing insurers and PBMs. This strategy impacts drug pricing, patient out-of-pocket costs, and insurance market dynamics in the U.S.

Increasing specialty drug costs lead to greater use of alternative funding programs in employer health plans, raising access and cost concerns amid rising drug prices.

Study reveals limited insurance coverage for multiple sclerosis drugs increases relapse risk, highlighting Medicare plan disparities and formulary restrictions.

Applied Policy names Brittany La Couture as VP of Health Policy, leveraging her Medicare Advantage and CMS expertise to enhance pharmaceutical reimbursement strategies.

Explore major U.S. health policy changes in 2025 affecting insurance access, Medicaid funding, vaccine advisory shifts, and regulatory reforms.

Amazon Pharmacy has expanded PillPack to Medicare, allowing seniors to use pre-sorted medication packets with insurance coverage, enhancing medication management and caregiver support.